Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice

被引:0
|
作者
Douglas M. McCarty
Julianne DiRosario
Kadra Gulaid
Smruti Killedar
Arie Oosterhof
Toin H. van Kuppevelt
Paul T. Martin
Haiyan Fu
机构
[1] The Ohio State University,The Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital
[2] The Ohio State University,Department of Pediatrics, College of Medicine and Public Health
[3] Radboud University Nijmegen Medical Center,Department of Biochemistry, Nijmegen Center for Molecular Life Sciences
来源
Metabolic Brain Disease | 2011年 / 26卷
关键词
MPS IIIB; Lysosomal storage disease; Heparan sulfate; Neuropathology; Glycobiosynthesis;
D O I
暂无
中图分类号
学科分类号
摘要
The primary pathology in mucopolysaccharidosis (MPS) IIIB is lysosomal storage of heparan sulfate (HS) glycosaminoglycans, leading to complex neuropathology and dysfunction, for which the detailed mechanisms remain unclear. Using antibodies that recognize specific HS glycoforms, we demonstrate differential cell-specific and domain-specific lysosomal HS-GAG distribution in MPS IIIB mouse brain. We also describe a novel neuron-specific brain HS epitope with broad, non-specific increase in the expression in all neurons in MPS IIIB mouse brain, including cerebellar granule neurons, which do not exhibit lysosomal storage pathology. This suggests that biosynthesis of certain HS glycoforms is enhanced throughout the CNS of MPS IIIB mice. Such a conclusion is further supported by demonstration of increased expression of multiple genes encoding enzymes essential in HS biosynthesis, including HS sulfotransferases and epimerases, as well as FGFs, for which HS serves as a co-receptor, in MPS IIIB brain. These data suggest that lysosomal storage of HS may lead to the increase in HS biosyntheses, which may contribute to the neuropathology of MPS IIIB by exacerbating the lysosomal HS storage.
引用
收藏
页码:9 / 19
页数:10
相关论文
共 50 条
  • [21] Membrane-tethered form of NAGLU used to elucidate pathogenesis of heparan sulfate in MPS IIIB mice
    Le, Steven Q.
    Sorensen, Alexander
    Dickson, Patricia I.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 78 - 78
  • [22] 6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway
    Zhang, LJ
    Beeler, DL
    Lawrence, R
    Lech, M
    Liu, J
    Davis, JC
    Shriver, Z
    Sasisekharan, R
    Rosenberg, RD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (45) : 42311 - 42321
  • [23] Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB
    De Pasquale, Valeria
    Scerra, Gianluca
    Scarcella, Melania
    D'Agostino, Massimo
    Pavone, Luigi Michele
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2021, 1868 (11):
  • [24] Heparan sulfate proteo glycanbiosynthesis enzymesas potential markers for the differential diagnosis of brain tumors
    Domanitskaya, N.
    Tsidulko, A. Y.
    Gaitan, A. S.
    Rubtsova, N. V.
    Aidagulova, S. V.
    Krivoshapkin, A. L.
    Grigorieva, E. V.
    FEBS JOURNAL, 2014, 281 : 470 - 471
  • [25] Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice
    Morimoto, Hideto
    Kida, Sachiho
    Yoden, Eiji
    Kinoshita, Masafumi
    Tanaka, Noboru
    Yamamoto, Ryuji
    Koshimura, Yuri
    Takagi, Haruna
    Takahashi, Kenichi
    Hirato, Tohru
    Minami, Kohtaro
    Sonoda, Hiroyuki
    MOLECULAR THERAPY, 2021, 29 (05) : 1853 - 1861
  • [26] Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLC-MS/MS
    Menkovic, Iskren
    Lavoie, Pamela
    Boutin, Michel
    Auray-Blais, Christiane
    BIOANALYSIS, 2019, 11 (08) : 727 - 740
  • [27] Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice
    Kowalewski, Bjoern
    Lamanna, William C.
    Lawrence, Roger
    Damme, Markus
    Stroobants, Stijn
    Padva, Michael
    Kalus, Ina
    Frese, Marc-Andre
    Luebke, Torben
    Luellmann-Rauch, Renate
    D'Hooge, Rudi
    Esko, Jeffrey D.
    Dierks, Thomas
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (26) : 10310 - 10315
  • [28] Do quantitative and qualitative differences in organ tissue distribution of heparan sulfate in mice solve some mysteries of protein expression?
    Linhardt, R
    Warda, M
    Mao, WJ
    Toida, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U362 - U362
  • [29] Do quantitative and qualitative differences in organ tissue distribution of heparan sulfate in mice solve some mysteries of protein expression?
    Linhardt, R
    Warda, M
    Mao, WJ
    Toida, T
    CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (12) : 1654 - 1654
  • [30] Comparison of dermatan sulfate and heparan sulfate concentrations in serum, cerebrospinal fluid and urine in patients with mucopolysaccharidosis type I receiving intravenous and intrathecal enzyme replacement therapy
    Zhang, Haoyue
    Dickson, Patricia, I
    Stiles, Ashlee R.
    Chen, Agnes H.
    Le, Steven Q.
    McCaw, Patricia
    Beasley, James
    Millington, David S.
    Young, Sarah P.
    CLINICA CHIMICA ACTA, 2020, 508 : 179 - 184